Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

219.16 +0.12 (+0.05%)
Official Closing Price Updated: 7:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
The Top 5 Analyst Questions From AbbVie’s Q3 Earnings Call
AbbVie’s third quarter results were marked by strong year-on-year revenue growth, driven primarily by continued momentum in its immunology and neuroscience portfolios. Management pointed to sales... 
Via StockStory
Topics Earnings
3 Dividend Stocks Down 11%, 29%, and 41% to Buy in November
These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on. 
Via The Motley Fool
Topics Intellectual Property
US Economic Resilience Fuels Dollar's Ascent Amidst Global Shifts
The United States economy is currently riding a wave of positive momentum, with a series of robust economic indicators signaling underlying strength and resilience. This optimistic outlook has, in... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
What the Options Market Tells Us About AbbVie
 
Via Benzinga
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Ironwood Pharma Stock Soars After FDA Grants Approval For Irritable Bowel Syndrome Drug In Pediatric Patients
Linzess is the first treatment approved for the disease in pediatric patients, the FDA said. 
Via Stocktwits
2 Healthcare Stocks for Individual Investors With a 10-Year Time Horizon
Healthcare has been an extraordinarily resilient industry to put cash to work in through the years. 
Via The Motley Fool
Topics Intellectual Property
ABBV Q3 Deep Dive: Immunology Growth and Pipeline Expansion Offset Margin Pressure
Pharmaceutical company AbbVie (NYSE:ABBV) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per... 
Via StockStory
Looking Into AbbVie Inc's Recent Short Interest
 
Via Benzinga
AbbVie's Earnings Outlook
 
Via Benzinga
My Favorite Dividend King to Buy in November
This member of dividend royalty checks off lots of boxes for investors. 
Via The Motley Fool
Topics Intellectual Property
2 Magnificent Dividend Stocks to Buy and Hold Forever
Some might call them boring businesses, but they have tremendous dividend growth track records. 
Via The Motley Fool
Topics Economy Intellectual Property
2 Top ETFs I Can't Wait to Buy More of in My Retirement Account This November
These ETFs are ideal retirement holdings. 
Via The Motley Fool
Topics ETFs Retirement Stocks
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
Via MarketBeat
Why AbbVie Stock Flopped on Friday
The market didn't exactly greet the company's latest earnings release with open arms. 
Via The Motley Fool
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant... 
Via MarketMinute
Topics Intellectual Property
Exploring the top movers within the S&P500 index during today's session.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
Via Chartmill
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
Discover which S&P500 stocks are making waves on Friday.
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Why AbbVie (ABBV) Shares Are Falling Today
Shares of pharmaceutical company AbbVie (NYSE:ABBV) fell 3.9% in the afternoon session after the company reported third-quarter results that were overshadowed by a steep drop in profitability and a... 
Via StockStory
Topics World Trade
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive. 
Via Benzinga
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend
AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfolio growth. 
Via Benzinga
Gapping S&P500 stocks in Friday's session
Friday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session. 
Via Chartmill
AbbVie Q3 2025 Earnings Call Transcript
AbbVie Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Economy
ABBVIE INC (NYSE:ABBV) Reports Mixed Q3 2025 Results with EPS Beat and Revenue Miss
AbbVie's Q3 2025 results show a mixed quarter with adjusted EPS beating estimates, but revenue missed and GAAP profit fell sharply. 
Via Chartmill
AbbVie Beats Third-Quarter Forecasts As Immunology Kingpin Grows 47%
AbbVie stock dipped early Friday, though the drug giant easily beat views. 
Via Investor's Business Daily
AbbVie’s (NYSE:ABBV) Q3 Sales Beat Estimates
Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q3 CY2025, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above... 
Via StockStory
Topics Earnings
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
Railway Pension Liquidates All 1.65M CCJ Shares Worth $122.8 Million
Railway Pension Liquidates All 1.65M CCJ Shares Worth $122.8 Million 
Via The Motley Fool
Topics Supply Chain
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.